More AdAlta Ltd. news
AdAlta Ltd.ASX: 1AD

GLP Toxicology study results

Oct 28, 2019 at 10:13 PM EDT · Issued by AdAlta Ltd.

Filed with ASX · Oct 28, 2019 at 10:13 PM EDT

On 6ix: 6ix.com/news/glp-toxicology-study-results

Adalta Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

AdAlta Ltd. on 6ix

In the deck

  • AdAlta — AusBiotech 201925 slidesOct 30, 2019

Story so far

  • GLP toxicology study commencesJul 16, 2019
  • Results of multi-dose toxicology studySep 19, 2017
  • Toxicology study and manufacturing updateJul 18, 2017

Earlier from AdAlta

  • Tim Oldham Appointed as Chief Executive OfficerOct 8, 2019
  • Receipt of R&D Tax IncentiveSep 17, 2019
  • AdAlta secures licensing deal with GE HealthcareSep 15, 2019
  • Executive team changesAug 11, 2019
  • GLP toxicology study commencesJul 15, 2019

Later from AdAlta

  • AdAlta awarded Biomedical Translation Bridge FundingDec 12, 2019
  • AD-214 Phase I strategy and timing updateJan 13, 2020
  • AdAlta Granted US Patent for AD-214Jan 29, 2020
  • Appendix 4C - quarterlyJan 30, 2020
  • AD-214 effective in gold standard pre-clinical animal modelMar 1, 2020
All AdAlta news releases↗

Follow AdAlta into a list and get an email when it puts out news.

Follow AdAlta
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer